Longevity Drug Index / Acarbose
Acarbose
An old, cheap diabetes pill that flattens blood sugar spikes and has robustly extended lifespan in male mice.
How it works
Acarbose blocks enzymes in the small intestine that break starch and table sugar down into glucose. Carbohydrates are absorbed more slowly, so blood sugar and insulin rise less after meals. The undigested carbohydrate passes to the colon, where gut bacteria ferment it into short-chain fatty acids such as butyrate.
How it could help longevity
Repeated blood sugar spikes damage proteins and blood vessels over time, and high insulin levels are linked to faster aging in many species. By smoothing these spikes, acarbose mimics some effects of eating less. The shift in gut bacteria and the fatty acids they produce may add further benefits for inflammation and metabolism.
Animal studies
- NIA Interventions Testing Program, 2014Acarbose given from early adulthood increased median lifespan by about 22% in male mice and about 5% in females, with gains in maximum lifespan in both sexes.
- Started in middle age, 2016Acarbose still extended lifespan when started at 16 months, again mainly in males.
- Combined with rapamycin, 2022Giving rapamycin and acarbose together produced larger lifespan gains than either drug alone.
Human studies
- STOP-NIDDM trial, 2002In people with impaired glucose tolerance, acarbose reduced progression to type 2 diabetes by about 25%.
- ACE trial, 2017In 6,522 Chinese patients with heart disease and impaired glucose tolerance, acarbose did not reduce heart attacks or strokes, but it reduced new cases of diabetes.
- AgingNo trial has tested acarbose for aging in healthy people.
Safety and side effects
Wind, bloating and diarrhoea are common and are the main reason people stop taking it; starting at a low dose helps. Rarely, it raises liver enzymes. On its own it does not cause low blood sugar, but if hypoglycaemia occurs with other diabetes drugs it must be treated with glucose, not table sugar.
Our view
The mouse data are strong and well replicated, the drug is cheap and its safety is well known from decades of diabetes use. But there are no human aging data, and the neutral ACE heart trial tempers expectations. It deserves a proper aging trial.
Sources
- Harrison et al., Aging Cell 2014: acarbose extends mouse lifespan preferentially in males
- Strong et al., Aging Cell 2016: acarbose started at 16 months
- Chiasson et al., Lancet 2002: STOP-NIDDM trial
- Holman et al., Lancet Diabetes Endocrinol 2017: ACE trial
- ClinicalTrials.gov: registered studies of Acarbose
Links open PubMed or ClinicalTrials.gov searches for each study.
Last reviewed 11 November 2026. General information, not medical advice. None of these drugs is approved to slow aging.